Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Post by FredTheVoiceon Apr 25, 2018 1:01pm

144 Views

Post# 27938869

Wait a second...

Thanks SmartMitch. You wrote a post ("wait a minute") that seems to me reflecting the reality of the situation. I would add that, yes, 12,50 a canadian share would be OK at the end of the year, BUT: do you really think that TH will gain only 30% in 8 months, with profits coming along the way ? You are very conservative ! Ok, the same way as TH management, you are trying to keep our expectations low........good job !

I still beleive that 15$ will easily be crossed this summer.......

Because than, the game thats called "SHOW ME THE MONEY" will be behind us.

FTV.

Bullboard Posts

Changing Europe’s dependency on HREE from China